Search Results
Dec 01, 2025, 06:00 ET Generate:Biomedicines inicia estudios globales de fase 3 de GB-0895
En este estudio, realizado con 96 personas con asma leve a moderada, GB-0895 fue generalmente bien tolerado en un amplio rango de dosis (de 10 mg a 1200 mg), demostró una farmacocinética proporcional a la dosis con una vida media de aproximadamente 89 días y produjo reducciones sostenidas en biomarcadores
More news about: Generate:Biomedicines
Dec 01, 2025, 04:00 ET AbbVie to Present Phase 3 ECLIPSE Data Demonstrating Atogepant (AQUIPTA®) Superiority Over Placebo in Achieving Pain Freedom for the Acute Treatment of Migraine at the 19th European Headache Congress
atogepant (60 mg) or placebo. The first attack (1:1 placebo to atogepant allocation) was the single attack used for the evaluation of the primary and 16 secondary efficacy endpoints. Following the up to 16-week DB period, subjects continued to treat qualifying migraine attacks with atogepant (60 mg) during
More news about: AbbVie
Nov 30, 2025, 09:22 ET ATYR DEADLINE: Faruqi & Faruqi Reminds aTyr Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 8, 2025 - ATYR
corticosteroid (OCS) dose at week 48, with the OCS dose reducing by an average of 2.79mg for 5.0 mg/kg efzofitimod compared to 3.52 mg for placebo. Complete steroid withdrawal was achieved for 52.6% of patients treated with 5.0 mg/kg efzofitimod versus 40.2% on placebo.After aTyr Pharma released the results,
More news about: Faruqi & Faruqi, LLP
Nov 28, 2025, 06:30 ET SUV Market worth $1,673.57 billion by 2032 | MarketsandMarkets™
Battery electric SUVs hold the largest share, followed by plug-in hybrid versions. The world's top-selling electric SUV models include the Tesla Model Y, MG ZS EV, Mercedes-Benz EQC, Audi e-tron, Kona Electric, and Volvo XC40. In the US and some European countries, OEMs are offering plug-in hybrid SUVs that
More news about: MarketsandMarkets
Nov 28, 2025, 04:06 ET China's First Domestic IL-23p19 Monoclonal Antibody: Innovent's PECONDLE® (Picankibart Injection) Received NMPA Approval
and 13.1%, p < 0.0001 for both); At week 52, the proportions of participants achieving PASI 90 and sPGA 0/1 in the picankibart 100 mg and 200 mg q12w maintenance treatment groups were stable and maintained at a high level; The proportion of participants who achieved PASI 75, PASI
More news about: Innovent Biologics
Nov 28, 2025, 00:13 ET The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma
its unique structural design, sac-TMT has demonstrated outstanding therapeutic potential in clinical studies.The results showed that sac-TMT 5 mg/kg monotherapy every 2 weeks demonstrated promising antitumor activity in participants with heavily pretreated advanced or metastatic UC, with a manageable
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nov 27, 2025, 06:59 ET Membrane Bioreactor Market worth $6.75 billion by 2030 - Exclusive Report by MarketsandMarkets™
the second-largest share due to its superior anti-fouling capabilities, allowing it to maintain high sludge concentrations (MLSS) of 10,000 to 15,000 mg/L, which enhances treatment efficiency and stability. Its design also supports easy cleaning through a gas-liquid mixed flow, reducing fouling and extending
More news about: MarketsandMarkets
Nov 27, 2025, 03:49 ET Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management
bofanglutide injection is the first GLP-1 RA globally to be evaluated in a head-to-head, parallel-group comparison with semaglutide 2.4 mg (Wegovy®) in Chinese adults with obesity or overweight, with or without type 2 diabetes. These studies are designed to comprehensively assess
More news about: Gan & Lee Pharmaceuticals
Nov 27, 2025, 01:01 ET Rare Cannabinoid Company Announces Black Friday Sale Featuring Up To 40% Off and Free Mood Mints
to skip cocktails.Mood Gummies - natural, vegan fresh mint and lime flavored gummies that each contain 5mg Delta-9-THC, 5mg CBC oil, and 25mg CBD oil.Mood Oil - a gluten-free, sugar-free, flavorless THC, CBC, and CBD oil for mood enhancement that
More news about: HC Ventures
Nov 26, 2025, 08:00 ET Novo Nordisk files for FDA approval of a higher dose of Wegovy® injection 7.2 mg
semaglutide 7.2 mg versus 2.4 mg or placebo, as was dysaesthesia. Serious adverse events were reported by 6.8% of participants with semaglutide 7.2 mg, 10.9% with semaglutide 2.4 mg, and 5.5% with placebo.2The new, higher dose of Wegovy® (semaglutide 7.2 mg) is currently under
More news about: NOVO NORDISK INC.
Nov 25, 2025, 22:51 ET FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC)
surgery or curative radiation.It is not known if UNLOXCYT is safe and effective in childrenThe recommended dosage of UNLOXCYT is 1,200 mg as an intravenous infusion over 60 minutes every 3 weeks.IMPORTANT SAFETY INFORMATIONWARNING AND PRECAUTIONSImmune-mediated
More news about: Sun Pharma
Nov 25, 2025, 09:00 ET BIOLASE Showcases Advanced YSGG Laser Solutions for Periodontal and Implant Care at GNYDM 2025
technology into their practice.BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE MG LLC.For updates and information on BIOLASE and laser dentistry, find BIOLASE online at
More news about: BIOLASE
Nov 25, 2025, 07:30 ET Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
administration, with less than 2% incidence of systemic injection/infusion-related reactions.Should the FDA approve the LEQEMBI IQLIK 500 mg SC dosing regimen (two 250 mg injections), the autoinjector could be used to administer a once-weekly starting dose, as an alternative to the current bi-weekly (every
More news about: Eisai Inc.
Nov 25, 2025, 07:30 ET Polly Plumbing Announces Official Launch in Tarrant County With a Neighbor-First Mission and a Promise of Better Home Service
neighborhoods, and soil movement that can affect slab foundations. According to public water data, North Texas water hardness commonly ranges between 140–180 mg/L, which can impact plumbing systems, fixtures, and water-using appliances.Additionally, engineering sources note that North Texas clay soils expand
More news about: Polly Plumbing
Nov 25, 2025, 04:00 ET Mazdutide 9mg Supplementary Application Accepted for Review by China's NMPA, Potentially Offering a Novel Drug Option for Moderate-to-Severe Obese Population
delighted that the supplementary application for mazdutide has been accepted. Our strategic portfolio—ranging from 2mg-4mg-6mg targeting the broad overweight/obese population, to the 3 mg-6mg-9mg dosage now targeting the severely obese population—is built upon profound scientific insight and clear market needs.
More news about: Innovent Biologics
Nov 24, 2025, 16:30 ET Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
of 200 mg twice daily or 150 mg twice daily, reduce the Verzenio dose to 100 mg twice daily with concomitant use of strong CYP3A inhibitors other than ketoconazole. In patients who have had a dose reduction to 100 mg twice daily due to adverse reactions, further reduce the Verzenio dose to 50 mg twice
More news about: Eli Lilly and Company
Nov 24, 2025, 16:01 ET Innocan Pharma Announces Promising Translational Evidence from a Pain Relief Study of Repeated LPT-CBD Administration in Goats
Two goats suffering from chronic and disabling painful condition were treated with subcutaneous Synthetic Liposomal Cannabidiol (LPT-CBD, 5 mg/kg) injections every six weeks for 10 months. Throughout the study, serial blood sampling was performed to assess CBD and its metabolite plasma concentrations
More news about: Innocan Pharma Corporation
Nov 24, 2025, 16:01 ET Innocan Pharma Announces Promising Translational Evidence from a Pain Relief Study of Repeated LPT-CBD Administration in Goats
Two goats suffering from chronic and disabling painful condition were treated with subcutaneous Synthetic Liposomal Cannabidiol (LPT-CBD, 5 mg/kg) injections every six weeks for 10 months. Throughout the study, serial blood sampling was performed to assess CBD and its metabolite plasma concentrations
More news about: Innocan Pharma Corporation
Nov 24, 2025, 12:00 ET Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting
lymphoma (MCL) and chronic lymphocytic leukemia (CLL).2,3 Jaypirca is a U.S. FDA-approved oral prescription medicine, 100 mg or 50 mg tablets taken as a once-daily 200 mg dose with or without food until disease progression or unacceptable toxicity.INDICATIONS FOR JAYPIRCA (pirtobrutinib)Jaypirca
More news about: Eli Lilly and Company
Nov 24, 2025, 07:00 ET Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer
patient at the 0.12 mg/kg dose level who was previously treated with cisplatin, pemetrexed, carboplatin and osimertinib had stable disease and received REQORSA for 32 cycles, or approximately 24 months, until disease progression occurred.A third patient who was at the 0.09 mg/kg dose level, previously
More news about: Genprex, Inc.
Nov 21, 2025, 10:30 ET UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
corticosteroid (OCS) dose at week 48, with the OCS dose reducing by an average of 2.79mg for 5.0 mg/kg efzofitimod compared to 3.52 mg for placebo. Complete steroid withdrawal was achieved for 52.6% of patients treated with 5.0 mg/kg efzofitimod versus 40.2% on placebo.After aTyr Pharma released the results,
More news about: Faruqi & Faruqi, LLP
Nov 21, 2025, 06:22 ET Weekly Recap: 14 Health Press Releases You Need to See
for $199 per monthThis introductory offer is good for the first two months of therapy and applies to the two lowest doses (0.25 mg and 0.5 mg) of Wegovy® or Ozempic®. After those two months, patients will move to the new standard monthly self-pay price which Novo
More news about: PR Newswire
Nov 21, 2025, 06:02 ET 14 Press Releases You Need to See This Week
for $199 per monthThis introductory offer is good for the first two months of therapy and applies to the two lowest doses (0.25 mg and 0.5 mg) of Wegovy® or Ozempic®. After those two months, patients will move to the new standard monthly self-pay price which Novo
More news about: PR Newswire
Nov 20, 2025, 13:16 ET Accord BioPharma, Inc. Announces FDA Approval of Denosumab Biosimilars OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu)
. JUBEREQ (denosumab-desu) injection is supplied in a 120 mg/1.7 mL (70 mg/mL) single-dose vial. Click here for
More news about: Accord BioPharma
Nov 20, 2025, 11:00 ET Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025
screening, open label (12-week period, participants will receive a single daily 10 mg dose of ampreloxetine), randomized withdrawal (eight-week period, double-blind, placebo-controlled, participants will receive a single daily 10 mg dose of placebo or ampreloxetine), and a long-term treatment extension. Secondary
More news about: Theravance Biopharma, Inc.